Market Overview

Cesca Therapeutics Snags Bullish HC Wainwright Initiation On CAR-T Opportunity

Cesca Therapeutics Snags Bullish HC Wainwright Initiation On CAR-T Opportunity

Cesca Therapeutics Inc (NASDAQ: KOOL) is poised to make much headway with its automated CAR-T manufacturing platform CAR-TXpress, according to H.C. Wainwright. 

CAR-T-cell therapy is a method of treating cancer by using a patient's immune system cells —  T cells — which are then modified by adding a gene in the lab for a special chimeric antigen receptor, or CAR, to attack cancer cells. CAR binds to a certain protein present in the patient's cancer cell.

The Analyst

Analyst Swayampakula Ramakanth initiated coverage of Cesca with a Buy and $1.50 price target.

The Thesis

Cesca's CAR-TXpress is likely to address the factors that are behind the high production costs of CAR-T cells, which could impede further advancements in CAR-T research and adoption, Ramakanth said in a Wednesday note.

The production costs are $100,000 per patient, the analyst said, naming five reasons for the high cost:

  • Insufficient starting T-cell material.
  • Labor- and time-intensive processing steps.
  • Expensive reagents and machinery.
  • Earge clean room footprints.
  • Complicated c-GMP compliance.

CAR-T therapies have a market opportunity of $8.5 billion by 2028, up from $15 million in 2017, according to H.C. Wainwright. 

Modular automation — a feature of CAR-TXpress — could be a game-changer, Ramakanth said.

"Currently, we project CAR-TXpress products to generate revenue of $548,000 in 2018, growing to $34 million by 2030." 

H.C. Wainwright projects opportunity for the company in the contract research development manufacturing organization market; Cesca has signed an exclusive license agreement in China and is likely to expand in the U.S., Ramakanth said. 

The Price Action

Cesca shares were down 1.87 percent at 53 cents at the time of publication Wednesday afternoon. 

Related Links:

The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

Latest Ratings for KOOL

Oct 2019HC Wainwright & Co.ReiteratesBuy
May 2018H.C. WainwrightInitiates Coverage OnBuy
Dec 2015Maxim GroupDowngradesBuyHold

View More Analyst Ratings for KOOL
View the Latest Analyst Ratings


Related Articles (KOOL)

View Comments and Join the Discussion!

Posted-In: HC Wainwright Swayampakula RamakanthAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

Latest Ratings

FBTruist SecuritiesMaintains310.0
GOOGLDeutsche BankMaintains2,250.0
FBWells FargoMaintains330.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at